Expanded algorithm for managing patients with acute decompensated heart failure

  • Joyce N. Njoroge
  • Baljash Cheema
  • Andrew P. Ambrosy
  • Stephen J. Greene
  • Sean P. Collins
  • Muthiah Vaduganathan
  • Alexandre Mebazaa
  • Ovidiu Chioncel
  • Javed Butler
  • Mihai Gheorghiade
Article

Abstract

Heart failure is a complex disease process, the manifestation of various cardiac and noncardiac abnormalities. General treatment approaches for heart failure have remained the same over the past decades despite the advent of novel therapies and monitoring modalities. In the same vein, the readmission rates for heart failure patients remain high and portend a poor prognosis for morbidity and mortality. In this context, development and implementation of improved algorithms for assessing and treating HF patients during hospitalization remains an unmet need. We propose an expanded algorithm for both monitoring and treating patients admitted for acute decompensated heart failure with the goal to improve post-discharge outcomes and decrease rates of rehospitalizations.

Keywords

Heart failure Acute decompensated heart failure, rehospitalizations HFrEF 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Muthiah Vaduganathan is supported by the NHLBI T32 postdoctoral training grant (T32HL007604); Dr. Andrew P. Ambrosy is supported by the NHLBI T32 postdoctoral training grant (5T32HL069749); Dr. Sean P. Collins is supported by grants through the AHA, PCORI, NIH, AHRQ, and Novartis and is a consultant for Novartis.

References

  1. 1.
    Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO (2013) Rehospitalization for heart failure. Probl Perspect JACC 61(4):391–403Google Scholar
  2. 2.
    O’Connor CM, Miller AB, Blair JE et al (2010) Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome study with Tolvaptan (EVEREST) program. Am Heart J 159:841–849CrossRefPubMedGoogle Scholar
  3. 3.
    Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJV, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA, for the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13):1482–1487CrossRefPubMedGoogle Scholar
  4. 4.
    Ramirez A, Abelmann WH (1974) Cardiac decompensation. NEJM 290(9):499–501CrossRefPubMedGoogle Scholar
  5. 5.
    Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, Collins S, Diercks D, Fonarow G, Hollander J, Kellerman A, Gheorghiade M, Kirk D, Levy P, Maisel A, Massie BM, O'Connor C, Pang P, Shah M, Sopko G, Stevenson L, Storrow A, Teerlink J (2010) National Heart, Lung and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. JACC. 56(5):343–351CrossRefPubMedGoogle Scholar
  6. 6.
    Hamo CE, Butler J, Gheorghiade M, Chioncel O (2016) The bumpy road to drug development for acute heart failure. Eur Heart J Supp 18(Supplement G):G19–G32CrossRefGoogle Scholar
  7. 7.
    Gheorghiade M, Braunwald E (2011) A proposed model for initial assessment and management of acute heart failure syndromes. JAMA 305:1702–1703CrossRefPubMedGoogle Scholar
  8. 8.
    Ponikowski P, Voors AA, Anker SD et al (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association of the ESC. Eur Heart J 37(27):2129–2200CrossRefPubMedGoogle Scholar
  9. 9.
    Cleland JG, Pennel D, Ray S, Murray G, MacFarlane P, Cowley A, Coats A, Lahiri A (1999) The Carvedilol Hibernation Reversible Ischemia Trial: Marker of Success (CHRISTMAS). Eur J Heart Fail 1:191–196CrossRefPubMedGoogle Scholar
  10. 10.
    Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A, Carvedilol hibernating reversible ischaemia trial: marker of success investigators, On behalf of the CHRISTMAS (Carvedilol Hibernating Reversible Ischaemia Trial: Maker of Success) investigators (2003) Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362:14–21CrossRefPubMedGoogle Scholar
  11. 11.
    Greene SJ, Vaduganathan M, Gheorghiade M (2017) Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. Eur J Heart Fail 19(7):870–872CrossRefPubMedGoogle Scholar
  12. 12.
    Adamsom PB, Magalski A, Braunschweig F et al (2003) Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived form an implantable monitoring system. J Am Coll Cardiol 41:565–571CrossRefGoogle Scholar
  13. 13.
    Zile MR, Bennett TD, St John Sutton M et al (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 118(14):1433–1441CrossRefPubMedGoogle Scholar
  14. 14.
    Stevenson LW, Perloff JK (1989) The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261:884–888CrossRefPubMedGoogle Scholar
  15. 15.
    Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen D, Zannad F, Anker SD, Rhodes A, McMurray J, Filippatos G, European Society of Cardiology, European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure. Eur J Heart Fail 12(5):423–433CrossRefPubMedGoogle Scholar
  16. 16.
    Ambrosy AP, Khan H, Udelson JE, Mentz RJ, Chioncel O, Greene SJ, Vaduganathan M, Subacuis HP, Konstam MA, Swedberg K, Zannad F, Maggioni AP, Gheorghiade M, Butler J (2016) Changes in dyspnea status during hospitalization and post-discharge health-related quality of life in hospitalized patients with heart failure: findings from the EVEREST trial. Circ Heart Fail. 9:e002458CrossRefPubMedGoogle Scholar
  17. 17.
    Pang PS, Collins SP, Sauser K, Andrei AC, Storrow AB, Hollander JE, Tavares M, Spinar J, Macarie C, Raev D, Nowak R, Gheorghiade M, Mebazaa A (2014) Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between Likert and visual analog scales. Acad Emerg Med 21(6):659–666CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    AbouEzzeddine OF, Lala A, Khazanie PP et al (2016) Evaluation of a provocative dyspnea severity score in acute heart failure. Am Heart J 172:34–41CrossRefPubMedGoogle Scholar
  19. 19.
    McGee S, Abernethy WB, Simel DL (1999) The rational clinical examination. Is this patient hypovolemic? JAMA 281:1022–1029CrossRefPubMedGoogle Scholar
  20. 20.
    Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen D, Zannad F, Anker SD, Rhodes A, McMurray J, Filippatos G, European Society of Cardiology, European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12:423–433CrossRefPubMedGoogle Scholar
  21. 21.
    Felker GM, Cuculich PS, Gheorghiade M (2006) The Valsalva maneuver: a bedside ‘biomarker’ for heart failure. Am J Med 119:117–122CrossRefPubMedGoogle Scholar
  22. 22.
    Knowles JH, Gorlin R, Storey CF (1956) Clinical test for pulmonary congestion with use of the Valsalva maneuver. JAMA 160:44–48CrossRefGoogle Scholar
  23. 23.
    Weilenmann D, Rickli H, Follath F, Kiowski W, Brunner-la Rocca HP (2002) Noninvasive evaluation of pulmonary capillary wedge pressure by BP response to the Valsalva maneuver. Chest 122:140–145CrossRefPubMedGoogle Scholar
  24. 24.
    Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, ESCAPE Investigators and ESCAPE Study Coordinators (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294:1625–1633CrossRefPubMedGoogle Scholar
  25. 25.
    Chioncel O, Collins SP, Greene SJ, Ambrosy AP, Vaduganathan M, Macarie C, Butler J, Gheorghiade M (2016) Natriuretic peptide-guided management in heart failure. J Cardiovasc Med 17(8):556–568CrossRefGoogle Scholar
  26. 26.
    Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata KI, Fukumoto H, Takano T (2004) Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6(3):295–300CrossRefPubMedGoogle Scholar
  27. 27.
    Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee and Investigators (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. JACC. 49:1943–1950CrossRefPubMedGoogle Scholar
  28. 28.
    Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A (2009) Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. JACC 53(25):2343–2348CrossRefPubMedGoogle Scholar
  29. 29.
    Ferre RM, Chioncel O, Pang PS, Lang RM, Gheorghiade M, Collins SP (2015) Acute heart failure: the role of focused emergency cardiopulmonary ultrasound in identification and early management. Eur J Heart Fail 17:1223–1227CrossRefPubMedGoogle Scholar
  30. 30.
    Goonewardena SN, Gemignani A, Ronan A, Vasaiwala S, Blair J, Brennan JM, Shah DP, Spencer KT (2008) Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging 1(5):595–601CrossRefPubMedGoogle Scholar
  31. 31.
    Van De Water JM, Miller TW (2003) Impedance cardiography: the next vital sign technology? Chest 123(6):2028–2033CrossRefGoogle Scholar
  32. 32.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Wilson Tang WH, Tsai EJ, Bruce L (2013) Wilkoff. 2013 ACCF/AHA guideline for the management of heart failure. Circulation 128:e240–e327CrossRefPubMedGoogle Scholar
  33. 33.
    Testani JM, Chen J, McCauley BD et al (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122:265–272CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G, on behalf of the EVEREST Trial investigators (2013) EVEREST trial investigators: Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 15:1401–1411CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Testani JM, Kimmel SE, Dries DL, Coca SG (2011) Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4(6):685–691CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Rossignol P, Cleland JG, Bhandari S et al (2012) Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 125:271–279CrossRefPubMedGoogle Scholar
  37. 37.
    Golwala HB et al (2013) Use of hydralazineisosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc 2:e000214CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Gheorghiade M, Braunwald E (2009) Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 302:2146–2147CrossRefPubMedGoogle Scholar
  39. 39.
    The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM 336:525–533CrossRefGoogle Scholar
  40. 40.
    Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC (2009) Use of aldosterone antagonists in heart failure. JAMA 302:1658–1665CrossRefPubMedGoogle Scholar
  41. 41.
    Schrier RW, Gheorghiade M (2011) Challenge of rehospitalizations for heart failure: potential of natriuretic doses of mineralocorticoid receptor antagonists. Am Heart J 161:221–223CrossRefPubMedGoogle Scholar
  42. 42.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM 341:709–717CrossRefPubMedGoogle Scholar
  43. 43.
    Gines P, Schrier RW (2009) Renal failure in cirrhosis. NEJM 361:1279–1290CrossRefPubMedGoogle Scholar
  44. 44.
    Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay S, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. NEJM 370(15):1383–1392CrossRefPubMedGoogle Scholar
  45. 45.
    Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, Li SX, Testani JM, Khan U, Krumholz HM (2013) Dominance of furosemide for loop diuretic therapy in heart failuretime to revisit the alternatives? JACC 61(14):1549–1550CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Müller K, Gamba G, Jaquet F, Hess B (2003) Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life. Eur J Heart Fail 5(6):793–801CrossRefPubMedGoogle Scholar
  47. 47.
    Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2006) Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 92(10):1434–1440CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC (1995) Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 57(6):601–609CrossRefPubMedGoogle Scholar
  49. 49.
    Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM (2015) A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 169(3):323–333CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Bleske BE, Welage LS, Kramer WG, Nicklas JM (1998) Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure. J Clin Pharmacol 38(8):708–714CrossRefPubMedGoogle Scholar
  51. 51.
    Elhassan EA, Schrier RW. Disorders of extracellular volume. Compr Clin Nephrol (4e). 2010. 80–93. PrintGoogle Scholar
  52. 52.
    Ellison DH (1991) The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Int Med 114(10):886–894CrossRefPubMedGoogle Scholar
  53. 53.
    Swedberg K, Komajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 376(9744):875–885CrossRefPubMedGoogle Scholar
  54. 54.
    Segura LM (2011) Dual-acting angiotensin receptor-neprilysin inhibition. Curr Hypertens Rep 13:74–78CrossRefPubMedGoogle Scholar
  55. 55.
    McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMedGoogle Scholar
  56. 56.
    Xie W, Zheng F, Song X, Zhong B, Yan L (2016) Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: network meta-analysis. Int J Cardiol 205:65–71CrossRefPubMedGoogle Scholar
  57. 57.
    Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray J, Solomon SD, PARADIGM-HF Investigators (2016) Influence of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 68(3):241–248CrossRefPubMedGoogle Scholar
  58. 58.
    Li PK, Chow KM, tal V d LMW e (2017) Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol 13(2):90–103CrossRefPubMedGoogle Scholar
  59. 59.
    Bart BA, Goldsmith SR, Lee KL et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. NEJM 367:2296–2304CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Costanzo MR, Negoianu D, Jaski BE, Bart BA, Heywood JT, Anand IS, Smelser JM, Kaneshige AM, Chomsky DB, Adler ED, Haas GJ, Watts JA, Nabut JL, Schollmeyer MP, Fonarow GC (2016) Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC: Heart Failure 4(2):95–105PubMedGoogle Scholar
  61. 61.
    Mehrotra R, Kathuria P Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure. Kidney Int Suppl 103:S67–S71Google Scholar
  62. 62.
    Cnossen TT, Kooman JP, Konings CJ (2010) Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif 20:146–152CrossRefGoogle Scholar
  63. 63.
    Nunez J, Gonazalez M, Minana G et al (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548CrossRefPubMedGoogle Scholar
  64. 64.
    Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1574–1585.  https://doi.org/10.1002/ejhf.813 CrossRefPubMedGoogle Scholar
  65. 65.
    Adams JKF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209–216CrossRefPubMedGoogle Scholar
  66. 66.
    Ments RJ, Kelly JP, von Lueder TG et al (2014) Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. JACC. 64(21):2281–2293CrossRefGoogle Scholar
  67. 67.
    Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JAC (2008) Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. JACC. 51:1775–1783CrossRefPubMedGoogle Scholar
  68. 68.
    Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet 373(9681):2125–2135CrossRefPubMedGoogle Scholar
  69. 69.
    Scirica BM, Bhatt D, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (SAVOR-TIMI 53). NEJM 369:1317–1326CrossRefPubMedGoogle Scholar
  70. 70.
    Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83–90CrossRefPubMedGoogle Scholar
  71. 71.
    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. NEJM 373(22):2117–2128CrossRefPubMedGoogle Scholar
  72. 72.
    Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM 377:644–657CrossRefPubMedGoogle Scholar
  73. 73.
    Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients: a systematic review and meta-analysis. JACC. 52:818–827CrossRefPubMedGoogle Scholar
  74. 74.
    Tang YD, Katz SD (2006) Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circ. 113:2454–2461CrossRefGoogle Scholar
  75. 75.
    Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJV, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880CrossRefPubMedGoogle Scholar
  76. 76.
    Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray J, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen D, RED-HF Committees, RED-HF Investigators (2013) Treatment of anemia with darbepoietin alfa in systolic heart failure. NEJM 368:1210–1219CrossRefPubMedGoogle Scholar
  77. 77.
    Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, for the NHLBI Heart Failure Clinical Research Network (2017) Effects of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency. JAMA 317(19):1958–1966CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Gerasimos F, Dimitrios F, Comin C et al (2013) Intravenous ferric carboxymaltose in iron-defcient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 15:1267–1276CrossRefGoogle Scholar
  79. 79.
    Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, for the CONFIRM-HF Investigators (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36(11):657–668CrossRefPubMedGoogle Scholar
  80. 80.
    van Velhuisen DJ, Ponikowski PI, van der Meer P et al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation; CIRCULATIONAHA 117:02749Google Scholar
  81. 81.
    Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M (2015) The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 12(4):220–229CrossRefPubMedGoogle Scholar
  82. 82.
    Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, Peterson ED, Curtis LH (2010) Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 303:1716–1722CrossRefPubMedGoogle Scholar
  83. 83.
    Harinstein ME, Flaherty JD, Fonarow GC, Mehra MR, Lang RM, Kim RJ, Cleland JG, Knight BP, Pang PS, Bonow RO, Gheorghiade M (2011) Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart 97:1607–1618CrossRefPubMedGoogle Scholar
  84. 84.
    Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. JACC. 35(5):1245–1255CrossRefPubMedGoogle Scholar
  85. 85.
    Dai S et al (2016) Kansas City Cardiomyopathy Questionnaire Utility in prediction of 30 day readmission rate in patients with chronic heart failure. Cardiol Res Pract 2016(2016):4571201PubMedPubMedCentralGoogle Scholar
  86. 86.
    Greene SJ, Maggioni AP, Fonarow GC et al (2015) Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. Eur J Heart Fail 17(1):98–108CrossRefPubMedGoogle Scholar
  87. 87.
    Greene SJ, Butler J, Fonarow GC et al (2017) Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail 20:281–291.  https://doi.org/10.1002/ejhf.1019 CrossRefPubMedGoogle Scholar
  88. 88.
    Metra M, Gheorghiade M, Bonow RO, Dei Cas L (2010) Postdischarge assessment after a heart failure hospitalization: the next step forward. Circ 122:1782–1785CrossRefGoogle Scholar
  89. 89.
    Flynn KE, Pina IL, Whellan DJ et al (2009) Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301(14):1451–1459CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Golwala H, Pandey A, Ju C, Butler J, Yancy C, Bhatt DL, Hernandez AF, Fonarow GC (2015) Temporal trends and factors associated with cardiac rehabilitation referral among patients hospitalized with heart failure findings from Get with the Guidelines—Heart Failure Registry. JACC. 66(8):917–926CrossRefPubMedGoogle Scholar
  91. 91.
    Varnfield M, Karunanithi M, Lee CK, Honeyman E, Arnold D, Ding H, Smith C, Walters DL (2014) Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomized controlled trial. Heart 100:1770–1779CrossRefPubMedGoogle Scholar
  92. 92.
    Abraham W et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet 377:658–666CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Joyce N. Njoroge
    • 1
  • Baljash Cheema
    • 1
  • Andrew P. Ambrosy
    • 2
  • Stephen J. Greene
    • 2
  • Sean P. Collins
    • 3
  • Muthiah Vaduganathan
    • 4
  • Alexandre Mebazaa
    • 5
    • 6
  • Ovidiu Chioncel
    • 7
    • 8
  • Javed Butler
    • 9
  • Mihai Gheorghiade
    • 1
  1. 1.Department of Medicine, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  2. 2.Duke Clinical Research Institute and Division of CardiologyDuke University Medical CenterDurhamUSA
  3. 3.Vanderbilt University Medical CenterNashvilleUSA
  4. 4.Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical SchoolBostonUSA
  5. 5.Department of Anesthesia and Critical Care, Inserm U942Hôpitaux Universitaires Saint-Louis-LariboisièreParisFrance
  6. 6.University Paris DiderotParisFrance
  7. 7.Institute of Emergency for Cardiovascular Diseases “Prof C.C.Iliescu”BucharestRomania
  8. 8.University of Medicine and Pharmacy Carol DavilaBucharestRomania
  9. 9.Department of MedicineUniversity of MississippiOxfordUSA

Personalised recommendations